Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish acute leukemia registry.

In English

Författare

Summary, in English

Most patients with acute myeloid leukemia (AML) are older, the median age is 71 years, and survival decreases rapidly with age. The achievement of complete remission and long-term survival mostly require intensive combination chemotherapy, but standard regimens are often believed to be too toxic for older patients. The Swedish Acute Leukemia Registry is unique and contains data on 98% of all patients diagnosed since 1997, irrespective of management. Comorbidity increases with age, but the distribution of AML-related risk factors is mostly similar in different age groups of patients older than 60 years old. In Sweden, most patients up to 75 years old are given intensive induction treatment with acceptable complete remission rates. Early death rates were always lower with intensive treatment compared with palliative treatment, thus, most patients up to 75 years and with AML both tolerate and benefit from intensive induction treatment.

Publiceringsår

2011

Språk

Engelska

Sidor

54-59

Publikation/Tidskrift/Serie

Clinical Lymphoma, Myeloma & Leukemia

Volym

11 Suppl 1

Dokumenttyp

Artikel i tidskrift

Förlag

CIG Media Group

Ämne

  • Cancer and Oncology

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 2152-2650